Inhibition of the PI3K pathway in cancers possessing PIK3CA mutations has demonstrated clinical benefit in breast and gynecologic malignancies, but the presence of these mutations alone does not predict sensitivity to these approaches [20]. Here, PIK3CA is linked to cancer.